Equity Overview
Price & Market Data
Price: $10.14
Daily Change: +$0.17 / 1.68%
Daily Range: $8.35 - $10.60
Market Cap: $195,490,080
Daily Volume: 83,729
Performance Metrics
1 Week: 22.17%
1 Month: 105.3%
3 Months: 90.24%
6 Months: -59.44%
1 Year: -59.44%
YTD: -59.44%
Company Details
Employees: 4
Sector: Biotechnology
Industry: NASDAQ
Country:
Details
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.